Company Leadership

Leslie Sloan, PhD

Chief Executive Officer

Dr. Sloan is a seasoned global executive with a proven track record of leading organizations, building high-performing cross-functional teams, and driving successful execution of drug development programs. With extensive experience in executive leadership, licensing, fundraising, and strategic portfolio management, Dr. Sloan has led efforts across multiple therapeutic areas, including rare diseases, oncology, and cardiovascular, as well as various modalities such as small molecules, peptides, and biologics.

Her expertise spans from executive strategy to R&D strategy and operational leadership, culminating in multiple successful BLA and NDA submissions. Dr. Sloan has played a key role in the regulatory approvals of several high-impact therapies, including Loargys® (pegzilarginase), Somatuline® Depot (lanreotide), Dysport® (abotulinumtoxinA), and XERMELO® (telotristat ethyl).

Before joining OmniNano, Dr. Sloan served as the SVP of Development and Operations at PanTher Therapeutics, where she led execution of the lead program, cross-functional collaboration, operational excellence, and resource management. Dr. Sloan successfully guided the development and execution of PanTher’s first IND, which earned FDA clearance.

 Prior to PanTher, Leslie served as Chief Operating Officer for Aeglea Biotherapeutics, a human enzyme therapeutics company. During her time at Aeglea, she oversaw portfolio programs from discovery through clinical development to achieve scientific, medical, and financial objectives. Previously, Leslie held several global leadership roles at Ipsen and Pfizer. While at Ipsen, she provided strategic and operational leadership for a global R&D portfolio focused on cancer, neuroscience, and rare diseases. She also served as the President Ipsen Bioscience. Leslie holds PhD and MS degrees in Bioorganic Chemistry from Yale University and a BS in Chemistry and Medical Biology from Southeastern Oklahoma State University. 

Chun Li, PhD

Founder

Professor and Director, John S. Dunn Laboratory in Imaging Sciences, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Editor, WIRES Nanobiotech. Nanomed

Co-Inventor of Opaxio (Paclitaxel Poliglumex), which advanced into phase III trials.

Diana S. Chow, PhD

Co-Founder

Paula & John J Lovoi Endowed Professor in Drug Discovery and Development

Director, Institute for Drug Education and Research (IDER), Department of Pharmacological and Pharmaceutical Sciences Houston, College of Pharmacy, University of Houston, TX

Inventor of Busulfex®, an FDA product

Inventor of multiple patents of developed formulations

Guorong Ma, PhD

Co-Founder & SVP

Dr. Ma is a co-founder and served as the founding chief executive of OmniNano until July 2024. He currently serves as SVP for Translational Science and Operations. Before joining OmniNano, Dr. Ma had been an independent consultant in the areas of biostatistics, clinical research, and regulatory strategy since 2020. Prior to that, Dr. Ma worked for Medtronic for 21 years with the increased responsibilities. For the last 11 years there, he was a senior director of clinical research for the Spine and Biologics Business (annual revenue > $3B).

Dr. Ma has extensive experiences in leading multiple functional/regional teams in clinical science, biostatistics, medical writing, scientific publications, imaging science, and global clinical trial management (US, EU, Japan, and China), as well as coordinating regulatory submissions and the development of regulatory strategies. He managed an organization of >40 employees with an annual operational budget of $20 million. He played critical roles in the premarket approval for a dozen of products by FDA, PMDA (Japan), and EMA (Europe). At Medtronic, his exceptional services were recognized by his receptions of Global Clinical Research Excellence Award and Technical Contributor of the Year Award. Dr. Ma received his PhD degree in plant genetics and master degree in statistics from Virginia Tech.

Scientific Advisors

  • Jason Fleming, MD

    Scientific Advisor

    Deputy Director, Simmons Cancer Center University of Texas Southwestern Medical Center

    Until recently, Dr. Fleming was Chair and Professor, Gastrointestinal Oncology, Moffitt Cancer Center (Tampa, FL).

    Prior to joining Moffitt, Dr. Fleming was a professor with tenure in the Department of Surgical Oncology at UT MD Anderson Cancer Center, where he served as chief of Pancreas Surgery and executive director of Perioperative Services.

    Dr. Fleming was co-director of the Pancreatic Cancer Moonshot Program, a Scientific and Medical Advisory board member for the Pancreatic Cancer Action Network (PanCAN).

  • Peiying Yang, PhD

    Scientific Advisor

    Associate Professor, Department of Palliative, Rehabilitation and Integrative Medicine, UT MD Anderson Cancer Center, Houston, TX

    Executive Committee, Society of Integrative Oncology (SIO, 2015-2019)

    Project manager in Pharmaceutical Development Center at MDACC (2006 – 2008)

    Scientific Advisor, Phoenix Biotechnology, Inc.

Top